Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6287 |
Tariquidar
XR9576,他立喹达 |
P-gp | Membrane transporter/Ion channel; Neuroscience |
Tariquidar (XR9576) 是一种特异性有效的P-糖蛋白抑制剂,Kd 为 5.1 nM。 | |||
T13087 |
Tariquidar methanesulfonate, hydrate
XR9576 methanesulfonate, hydrate |
Others | Others |
Tariquidar methanesulfonate, hydrate is a potent and specific P-glycoprotein (P-gp) inhibitor(Kd of 5.1 nM). | |||
T72186 |
Tariquidar dihydrochloride
XR9576 dihydrochloride |
||
Tariquidar dihydrochloride (XR9576 dihydrochloride) 是一种有效的特异性 P-glycoprotein(P-gp) 抑制剂,Kd 为 5.1 nM。 | |||
T6287L |
Tariquidar dimesylate
D 06008,XR9576,D06008,XR 9576,Tariquidar dimesilate,XR-9576 |
||
Tariquidar is a P-glycoprotein inhibitor undergoing research as an adjuvant against multidrug resistance in cancer. Tariquidar non-competitively binds to the p-glycoprotein transporter, thereby inhibiting transmembrane transport of anticancer drugs. | |||
T68568 |
Encequidar, HCl
|
||
Encequidar, also known as HM-30181, is an oral P-glycoprotein (P-gp) inhibitor developed to enhance the oral bioavailability of P-gp substrate drugs. Encequidar showed the highest potency (IC(50)=0.63nM) among several MDR1 inhibitors, including cycloporin A, XR9576, and GF120918, and effectively blocked transepithelial transport of paclitaxel in MDCK monolayers (IC(50)=35.4nM). Encequidar is currently under clinical trials. |